Page last updated: 2024-10-30

leflunomide and Arthritis, Juvenile Chronic

leflunomide has been researched along with Arthritis, Juvenile Chronic in 24 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Research Excerpts

ExcerptRelevanceReference
"Effectiveness of leflunomide renders it a potent treatment option in rheumatoid arthritis."8.87Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. ( Behrens, F; Burkhardt, H; Koehm, M, 2011)
"Chronic anterior uveitis is a serious complication of juvenile idiopathic arthritis (JIA); disease flares are highly associated with loss of vision."5.42Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. ( Benseler, SM; Bichler, J; Haas, JP; Hügle, B; Krumrey-Langkammerer, M, 2015)
"Effectiveness of leflunomide renders it a potent treatment option in rheumatoid arthritis."4.87Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. ( Behrens, F; Burkhardt, H; Koehm, M, 2011)
"In patients with polyarticular juvenile rheumatoid arthritis, methotrexate and leflunomide both resulted in high rates of clinical improvement, but the rate was slightly greater for methotrexate."2.71Leflunomide or methotrexate for juvenile rheumatoid arthritis. ( Calvo, I; Horneff, G; Jung, LK; Lahdenne, P; Mouy, R; Saurenmann, RK; Silverman, E; Simpson, K; Spiegel, L; Stewart, JA; Strand, V; Szer, IS, 2005)
"Juvenile idiopathic arthritis is the most frequent chronic rheumatic disease in childhood."2.53The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis. ( Horneff, G; Hügle, B, 2016)
"Before the biologic era, treatment of juvenile idiopathic arthritis (JIA) was often highly unsatisfactory, with children forced to endure the ill effects of lifelong disease, including pain and stiffness, disability, and even increased risk of mortality."2.49Treatment of juvenile idiopathic arthritis in the biologic age. ( Cron, RQ; Stoll, ML, 2013)
"Many exciting developments in the treatment of juvenile idiopathic arthritis (JIA) have emerged recently, including new tools to assess the results of clinical trials (eg, the definition of remission and a radiologic scoring tool)."2.43Update on the medical treatment of juvenile idiopathic arthritis. ( Hashkes, PJ; Laxer, RM, 2006)
"Prognostic factors in juvenile rheumatoid arthritis (JRA) include polyarticular onset, polyarticular disease course, and rheumatoid factor positivity; in the systemic onset subtype, persistence of systemic features at 6 months after onset confers a worse prognosis."2.41Current treatment of juvenile rheumatoid arthritis. ( Ilowite, NT, 2002)
" Efficacy and rate of adverse events (AEs) were evaluated during a 24-month period after tocilizumab commencement."1.56Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis. ( Aalto, K; Backström, M; Grönlund, MM; Kröger, L; Markula-Patjas, K; Putto-Laurila, A; Remes-Pakarinen, T; Vähäsalo, P, 2020)
"Juvenile idiopathic arthritis is the most common chronic rheumatic disease of childhood resulting in disability in untreated cases."1.51Leflunomide treatment in juvenile idiopathic arthritis. ( Ayaz, NA; Çakan, M; Çakmak, F; Karadağ, ŞG; Sönmez, HE; Tanatar, A, 2019)
"A 10-year-old girl with juvenile idiopathic arthritis in remission presented with a flare of her arthritis."1.48Juvenile idiopathic arthritis flare due to rice bodies in the knee of a 10-year-old girl. ( Barrow, M; Faller, G; Haagensen, M, 2018)
"Of these 22 patients, 16 had varicella and 6 had herpes zoster."1.43Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression. ( Aeschlimann, F; Baer, W; Berthet, G; Cannizzaro, E; Heininger, U; Hofer, M; Kaiser, D; Leuvenink, R; Schroeder, S; Woerner, A, 2016)
"Chronic anterior uveitis is a serious complication of juvenile idiopathic arthritis (JIA); disease flares are highly associated with loss of vision."1.42Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. ( Benseler, SM; Bichler, J; Haas, JP; Hügle, B; Krumrey-Langkammerer, M, 2015)
"Methotrexate, the mainstay of treatment in Juvenile idiopathic arthritis, might not be effective in a few patients of polyarticular and systemic onset juvenile idiopathic arthritis."1.38Leflunomide in systemic onset Juvenile idiopathic arthritis. ( Dewan, V; Jahan, A; Yadav, TP, 2012)
"Leflunomide treatment, as employed in actual clinical practice, was well tolerated and resulted in substantial improvements in joint and functional status outcomes in children with JIA."1.36Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. ( Foeldvari, I; Wierk, A, 2010)
"Following repeated liver biopsy, autoimmune hepatitis was assumed and prednisolone and azathioprine were initiated."1.35[Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report]. ( Hartmann, U; Reuss-Borst, M; Schmitt, S, 2008)
" Five patients withdrew because of failure to maintain efficacy, 2 withdrew their consent, and 1 withdrew because of an adverse event."1.33Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. ( Duffy, C; Goldsmith, D; Hawkins, D; Howard, P; Petty, R; Schanberg, L; Silverman, E; Spiegel, L; Strand, V, 2005)
"Leflunomide is a pyrimidine synthesis inhibitor used in the treatment of rheumatoid arthritis."1.33Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis. ( Bhargava, VO; Kovacs, SJ; Ludden, TM; Shi, J; Wang, Y, 2005)

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (37.50)29.6817
2010's12 (50.00)24.3611
2020's3 (12.50)2.80

Authors

AuthorsStudies
Broekaert, IJ3
Klein, A3
Windschall, D3
Rogalski, B3
Weller-Heinemann, F3
Oommen, P3
Küster, M3
Foeldvari, I4
Minden, K3
Hospach, A3
Hufnagel, M3
Berger, T3
Geikowski, T3
Quietzsch, J3
Horneff, G5
Brunelli, JB1
Silva, CA1
Pasoto, SG1
Saa, CGS1
Kozu, KT1
Goldenstein-Schainberg, C1
Leon, EP1
Vendramini, MBG1
Fontoura, N1
Bonfa, E1
Aikawa, NE1
Faller, G1
Haagensen, M1
Barrow, M1
Rocha, FAC1
Landim, JIVD1
Nour, ML1
Filho, VFP1
da Rocha, LN1
da Silva, MFC1
Rocha, HAL1
Ayaz, NA1
Karadağ, ŞG1
Çakmak, F1
Çakan, M1
Tanatar, A1
Sönmez, HE1
Grönlund, MM1
Remes-Pakarinen, T1
Kröger, L1
Markula-Patjas, K1
Backström, M1
Putto-Laurila, A1
Aalto, K1
Vähäsalo, P1
Molina, C1
Modesto, C1
Martín-Begué, N1
Arnal, C1
Stoll, ML1
Cron, RQ1
Alcântara, AC1
Leite, CA1
Leite, AC1
Sidrim, JJ1
Silva, FS1
Rocha, FA1
Bichler, J1
Benseler, SM1
Krumrey-Langkammerer, M1
Haas, JP1
Hügle, B2
Leuvenink, R1
Aeschlimann, F1
Baer, W1
Berthet, G1
Cannizzaro, E1
Hofer, M1
Kaiser, D1
Schroeder, S1
Heininger, U1
Woerner, A1
Wierk, A1
Behrens, F1
Koehm, M1
Burkhardt, H1
Jahan, A1
Dewan, V1
Yadav, TP1
Fantini, F1
Gao, JS1
Wu, H1
Tian, J1
Silverman, E2
Spiegel, L2
Hawkins, D1
Petty, R1
Goldsmith, D1
Schanberg, L1
Duffy, C1
Howard, P1
Strand, V2
Mouy, R1
Jung, LK1
Saurenmann, RK1
Lahdenne, P1
Calvo, I1
Szer, IS1
Simpson, K1
Stewart, JA1
Shi, J1
Kovacs, SJ1
Wang, Y1
Ludden, TM1
Bhargava, VO1
Passo, M1
Hashkes, PJ1
Laxer, RM1
Hartmann, U1
Schmitt, S1
Reuss-Borst, M1
Ilowite, NT1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients: A Randomized Double-Blind Controlled Study[NCT00506896]Phase 260 participants (Actual)Interventional2004-07-31Completed
The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828]176 participants (Anticipated)Interventional2019-08-02Recruiting
Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated With Biologic Agents and/or Methotrexate. A PRINTO/PRES Registry[NCT01399281]9,000 participants (Anticipated)Observational2011-12-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

7 reviews available for leflunomide and Arthritis, Juvenile Chronic

ArticleYear
Treatment of juvenile idiopathic arthritis in the biologic age.
    Rheumatic diseases clinics of North America, 2013, Volume: 39, Issue:4

    Topics: Abatacept; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Mo

2013
The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:5

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Drug Therapy, Combination; Humans; H

2016
Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
    Current opinion in rheumatology, 2011, Volume: 23, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheuma

2011
[New drugs and treatment strategies for rheumatoid arthritis].
    Recenti progressi in medicina, 2003, Volume: 94, Issue:9

    Topics: Adalimumab; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anti

2003
Emerging therapies in juvenile rheumatoid/idiopathic arthritis.
    Current problems in pediatric and adolescent health care, 2006, Volume: 36, Issue:3

    Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agen

2006
Update on the medical treatment of juvenile idiopathic arthritis.
    Current rheumatology reports, 2006, Volume: 8, Issue:6

    Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Juvenile; Child; Chil

2006
Current treatment of juvenile rheumatoid arthritis.
    Pediatrics, 2002, Volume: 109, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arth

2002

Trials

2 trials available for leflunomide and Arthritis, Juvenile Chronic

ArticleYear
[Treatment of patients with juvenile rheumatoid arthritis with combination of leflunomide and methotrexate].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2003, Volume: 41, Issue:6

    Topics: Adolescent; Arthritis, Juvenile; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans;

2003
Leflunomide or methotrexate for juvenile rheumatoid arthritis.
    The New England journal of medicine, 2005, Apr-21, Volume: 352, Issue:16

    Topics: Administration, Oral; Adolescent; Alanine Transaminase; Analysis of Variance; Antirheumatic Agents;

2005
Leflunomide or methotrexate for juvenile rheumatoid arthritis.
    The New England journal of medicine, 2005, Apr-21, Volume: 352, Issue:16

    Topics: Administration, Oral; Adolescent; Alanine Transaminase; Analysis of Variance; Antirheumatic Agents;

2005
Leflunomide or methotrexate for juvenile rheumatoid arthritis.
    The New England journal of medicine, 2005, Apr-21, Volume: 352, Issue:16

    Topics: Administration, Oral; Adolescent; Alanine Transaminase; Analysis of Variance; Antirheumatic Agents;

2005
Leflunomide or methotrexate for juvenile rheumatoid arthritis.
    The New England journal of medicine, 2005, Apr-21, Volume: 352, Issue:16

    Topics: Administration, Oral; Adolescent; Alanine Transaminase; Analysis of Variance; Antirheumatic Agents;

2005

Other Studies

15 other studies available for leflunomide and Arthritis, Juvenile Chronic

ArticleYear
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
    Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di

2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
    Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di

2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
    Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di

2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
    Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di

2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
    Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di

2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
    Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di

2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
    Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di

2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
    Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di

2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
    Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di

2023
Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.
    Clinical rheumatology, 2020, Volume: 39, Issue:2

    Topics: Adalimumab; Adolescent; Adult; Antibodies; Antibody Formation; Antirheumatic Agents; Arthritis, Juve

2020
Juvenile idiopathic arthritis flare due to rice bodies in the knee of a 10-year-old girl.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2018, Oct-02, Volume: 108, Issue:10

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis,

2018
Long-term breastfeeding influences disease activity in a low-income juvenile idiopathic arthritis cohort.
    Clinical rheumatology, 2019, Volume: 38, Issue:8

    Topics: Abatacept; Adalimumab; Adolescent; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthriti

2019
Leflunomide treatment in juvenile idiopathic arthritis.
    Rheumatology international, 2019, Volume: 39, Issue:9

    Topics: Adolescent; Arthritis, Juvenile; Biological Products; Child; Child, Preschool; Drug Substitution; Fe

2019
Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
    Rheumatology (Oxford, England), 2020, 04-01, Volume: 59, Issue:4

    Topics: Adolescent; Alanine Transaminase; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis

2020
Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis.
    Clinical rheumatology, 2013, Volume: 32, Issue:11

    Topics: Adolescent; Adult; Antirheumatic Agents; Arthritis, Juvenile; Child; Chronic Disease; Female; Humans

2013
A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis.
    The Journal of rheumatology, 2014, Volume: 41, Issue:2

    Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Drug Therapy, Combin

2014
Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
    Scandinavian journal of rheumatology, 2015, Volume: 44, Issue:4

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Chronic Disease; Cohort Studies;

2015
Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression.
    Pediatric rheumatology online journal, 2016, Jun-02, Volume: 14, Issue:1

    Topics: Acyclovir; Adolescent; Antirheumatic Agents; Antiviral Agents; Arthritis, Juvenile; Chickenpox; Chil

2016
Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice.
    The Journal of rheumatology, 2010, Aug-01, Volume: 37, Issue:8

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Child; Child, Preschool; F

2010
Leflunomide in systemic onset Juvenile idiopathic arthritis.
    Indian pediatrics, 2012, Volume: 49, Issue:9

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Female; Humans; Isoxazoles; Lefl

2012
Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Arthritis and rheumatism, 2005, Volume: 52, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents;

2005
Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis.
    Journal of pharmacokinetics and pharmacodynamics, 2005, Volume: 32, Issue:3-4

    Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Body Weight; Child; Child, Preschool; Drug Ad

2005
[Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report].
    Zeitschrift fur Rheumatologie, 2008, Volume: 67, Issue:5

    Topics: Adalimumab; Adolescent; Alanine Transaminase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani

2008